David Hagerty - Conatus Pharmaceuticals Executive Vice President Clinical Development
President
Mr. David T. Hagerty, M.D is the Executive Vice President, Clinical development since October 2014. Dr. Hagerty has over 18 years of experience in the pharmaceutical and biotechnology industries. Dr. Hagerty was an independent consultant in clinical development since April 2013. He served as Senior Vice President and Chief Medical Officer at Ardea Biosciences from 2011 to 2013. He previously served as a Vice President of Immunology and Rheumatology Clinical Research at Biogen Idec Inc. from 2006 to 2011, where he led the clinical development of rituximab for rheumatoid arthritis and lupus with joint development partner Genentech. Previously, Dr. Hagerty advanced through several management roles at the BristolMyers Squibb Pharmaceutical Research Institute from 1997 through 2006, most recently as Executive Director of Immunology Global Clinical Research and medical lead for the abatacept clinical development program. His earlier career included faculty and laboratory research duties at Washington University School of Medicine. Dr. Hagerty served for five years in the Medical Corporationration of the United States Navy, and was recalled to Active Duty in Operation Desert Storm since 2014.
| Age | 59 |
| Tenure | 10 years |
| Phone | 858 376-2600 |
| Web | www.conatuspharma.com |
Conatus Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (34.7836) % which means that it has lost $34.7836 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (51.6279) %, meaning that it created substantial loss on money invested by shareholders. Conatus Pharmaceuticals' management efficiency ratios could be used to measure how well Conatus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.The company currently holds 439 K in liabilities with Debt to Equity (D/E) ratio of 2.0, which is about average as compared to similar companies. Conatus Pharmaceuticals has a current ratio of 6.01, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Conatus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Conatus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Conatus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Conatus to invest in growth at high rates of return. When we think about Conatus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Andy Larkin | Summit Materials | N/A | |
| Brian Harris | Summit Materials | 68 | |
| Mikel Evans | Summit Materials | 47 | |
| Scott Toop | The Wendys Co | 60 | |
| Noel Ryan | Summit Materials | N/A | |
| Douglas Rauh | Summit Materials | 55 | |
| Kevin Gill | Summit Materials | 55 | |
| Damian Murphy | Summit Materials | 46 | |
| Anne Benedict | Summit Materials | 46 | |
| Robert Bafundo | Rave Restaurant Group | 62 | |
| Thomas Beck | Summit Materials | 67 | |
| Karli Anderson | Summit Materials | 51 | |
| Darrell Ligten | The Wendys Co | 49 | |
| Deon MacMillan | Summit Materials | 47 | |
| Karl Watson | Summit Materials | 53 | |
| Michael Brady | Summit Materials | 51 | |
Management Performance
| Return On Equity | -51.63 | |||
| Return On Asset | -34.78 |
Conatus Pharmaceuticals Leadership Team
Elected by the shareholders, the Conatus Pharmaceuticals' board of directors comprises two types of representatives: Conatus Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Conatus. The board's role is to monitor Conatus Pharmaceuticals' management team and ensure that shareholders' interests are well served. Conatus Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Conatus Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Edward Smith, Senior Vice President - Regulatory Affairs and Quality Assurance | ||
| Michelle Vandertie, Acting Principal Accounting Officer | ||
| Dan Kisner, Additional Independent Director | ||
| James Scopa, Independent Director | ||
| Steven Mento, Co-Founder, CEO and President and Director | ||
| Daniel Kisner, Additional Independent Director | ||
| Preston Klassen, Additional Independent Director | ||
| David Hale, Independent Chairman of the Board | ||
| Harold Wart, Independent Director | ||
| William LaRue, Additional Independent Director | ||
| Alfred Spada, Co-Founder, Chief Scientific Officer and Executive VP of RandD | ||
| Charles Cashion, CFO, Senior Vice President of Finance, Secretary | ||
| Daniel Ripley, Senior Vice President - Business Development, Program and Alliance Management | ||
| Keith Marshall, CFO, Principal Financial Officer, COO, Executive Vice President | ||
| Louis Lacasse, Independent Director | ||
| Shahzad Malik, Independent Director | ||
| David Hagerty, Executive Vice President Clinical Development |
Conatus Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Conatus Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -51.63 | |||
| Return On Asset | -34.78 | |||
| Profit Margin | (0.57) % | |||
| Operating Margin | (46.04) % | |||
| Current Valuation | (8.27 M) | |||
| Shares Outstanding | 33.17 M | |||
| Shares Owned By Insiders | 2.80 % | |||
| Shares Owned By Institutions | 13.92 % | |||
| Number Of Shares Shorted | 130.66 K | |||
| Price To Earning | (5.19) X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Conatus Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Conatus Pharmaceuticals' short interest history, or implied volatility extrapolated from Conatus Pharmaceuticals options trading.
Pair Trading with Conatus Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Conatus Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Conatus Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Microsoft could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Microsoft when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Microsoft - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Microsoft to buy it.
The correlation of Microsoft is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Microsoft moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Microsoft moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Microsoft can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the Conatus Pharmaceuticals information on this page should be used as a complementary analysis to other Conatus Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Other Consideration for investing in Conatus Stock
If you are still planning to invest in Conatus Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Conatus Pharmaceuticals' history and understand the potential risks before investing.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios |